VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice

Terry W. Moody; James Dudek; Halina Zakowicz; James Walters; Robert T. Jensen; Emmanual Petricoin; Chris Couldrey; Jeff E. Green

doi:10.1016/j.lfs.2003.07.043

VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice

Terry W. Moody^*, James Dudek, Halina Zakowicz, James Walters, Robert T. Jensen, Emmanual Petricoin, Chris Couldrey, Jeff E. Green

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

The effects of a vasoactive intestinal peptide (VIP) receptor antagonist on mammary carcinogenesis were investigated using the C3(1)SV40T antigen (ag) mice. Ten μg/day VIPhybrid (VIPhyb) administered daily subcutaneously increased significantly the survival of C3(1)SV40Tag mice. At 5.2 months, VIPhyb significantly reduced the mammary tumor burden in C3(1)SV40Tag mice relative to control animals. ¹²⁵I-VIP bound with high affinity to mouse mammary tumor homogenate. Because (Lys¹⁵, Arg¹⁶, Leu²⁷)VIP^1-7GRF^8-27 (VPAC₁ selective) but not Ro25-1553 (VPAC₂ selective) inhibited specific ¹²⁵I-VIP binding to mammary tumor membranes with high affinity, VPAC₁ receptors predominate. By RT-PCR, VPAC₁ receptor mRNA was detected in mammary tumors. By Western blot, a major 60 Kdalton band was detected in mammary tumor extracts using VPAC₁ receptor antisera. By immunocytochemistry, VPAC₁-R immunostaining was detected in the cytosol and plasma membrane but not the nucleus of fixed mammary tumor tissue. Using laser capture microdissected tumor cells and surface enhanced laser desorption/ionization (SELDI) techniques on mammary tumor cells, the proteomic profile was altered in mice treated with VIPhyb. Because VPAC₁ receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer.

Original language	English
Pages (from-to)	1345-1357
Number of pages	13
Journal	Life Sciences
Volume	74
Issue number	11
DOIs	https://doi.org/10.1016/j.lfs.2003.07.043
State	Published - 30 Jan 2004
Externally published	Yes

Keywords

Chemoprevention
Mammary carcinogenesis
Proteomics
Transgenic mice
VIP receptor antagonist

Access to Document

10.1016/j.lfs.2003.07.043

Cite this

@article{ed064b806bdd4b5698cd9d24f8276c12,

title = "VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice",

abstract = "The effects of a vasoactive intestinal peptide (VIP) receptor antagonist on mammary carcinogenesis were investigated using the C3(1)SV40T antigen (ag) mice. Ten μg/day VIPhybrid (VIPhyb) administered daily subcutaneously increased significantly the survival of C3(1)SV40Tag mice. At 5.2 months, VIPhyb significantly reduced the mammary tumor burden in C3(1)SV40Tag mice relative to control animals. 125I-VIP bound with high affinity to mouse mammary tumor homogenate. Because (Lys15, Arg16, Leu27)VIP1-7GRF8-27 (VPAC1 selective) but not Ro25-1553 (VPAC2 selective) inhibited specific 125I-VIP binding to mammary tumor membranes with high affinity, VPAC1 receptors predominate. By RT-PCR, VPAC1 receptor mRNA was detected in mammary tumors. By Western blot, a major 60 Kdalton band was detected in mammary tumor extracts using VPAC1 receptor antisera. By immunocytochemistry, VPAC1-R immunostaining was detected in the cytosol and plasma membrane but not the nucleus of fixed mammary tumor tissue. Using laser capture microdissected tumor cells and surface enhanced laser desorption/ionization (SELDI) techniques on mammary tumor cells, the proteomic profile was altered in mice treated with VIPhyb. Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer.",

keywords = "Chemoprevention, Mammary carcinogenesis, Proteomics, Transgenic mice, VIP receptor antagonist",

author = "Moody, {Terry W.} and James Dudek and Halina Zakowicz and James Walters and Jensen, {Robert T.} and Emmanual Petricoin and Chris Couldrey and Green, {Jeff E.}",

year = "2004",

month = jan,

day = "30",

doi = "10.1016/j.lfs.2003.07.043",

language = "English",

volume = "74",

pages = "1345--1357",

journal = "Life Sciences",

issn = "0024-3205",

number = "11",

}

TY - JOUR

T1 - VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice

AU - Moody, Terry W.

AU - Dudek, James

AU - Zakowicz, Halina

AU - Walters, James

AU - Jensen, Robert T.

AU - Petricoin, Emmanual

AU - Couldrey, Chris

AU - Green, Jeff E.

PY - 2004/1/30

Y1 - 2004/1/30

N2 - The effects of a vasoactive intestinal peptide (VIP) receptor antagonist on mammary carcinogenesis were investigated using the C3(1)SV40T antigen (ag) mice. Ten μg/day VIPhybrid (VIPhyb) administered daily subcutaneously increased significantly the survival of C3(1)SV40Tag mice. At 5.2 months, VIPhyb significantly reduced the mammary tumor burden in C3(1)SV40Tag mice relative to control animals. 125I-VIP bound with high affinity to mouse mammary tumor homogenate. Because (Lys15, Arg16, Leu27)VIP1-7GRF8-27 (VPAC1 selective) but not Ro25-1553 (VPAC2 selective) inhibited specific 125I-VIP binding to mammary tumor membranes with high affinity, VPAC1 receptors predominate. By RT-PCR, VPAC1 receptor mRNA was detected in mammary tumors. By Western blot, a major 60 Kdalton band was detected in mammary tumor extracts using VPAC1 receptor antisera. By immunocytochemistry, VPAC1-R immunostaining was detected in the cytosol and plasma membrane but not the nucleus of fixed mammary tumor tissue. Using laser capture microdissected tumor cells and surface enhanced laser desorption/ionization (SELDI) techniques on mammary tumor cells, the proteomic profile was altered in mice treated with VIPhyb. Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer.

AB - The effects of a vasoactive intestinal peptide (VIP) receptor antagonist on mammary carcinogenesis were investigated using the C3(1)SV40T antigen (ag) mice. Ten μg/day VIPhybrid (VIPhyb) administered daily subcutaneously increased significantly the survival of C3(1)SV40Tag mice. At 5.2 months, VIPhyb significantly reduced the mammary tumor burden in C3(1)SV40Tag mice relative to control animals. 125I-VIP bound with high affinity to mouse mammary tumor homogenate. Because (Lys15, Arg16, Leu27)VIP1-7GRF8-27 (VPAC1 selective) but not Ro25-1553 (VPAC2 selective) inhibited specific 125I-VIP binding to mammary tumor membranes with high affinity, VPAC1 receptors predominate. By RT-PCR, VPAC1 receptor mRNA was detected in mammary tumors. By Western blot, a major 60 Kdalton band was detected in mammary tumor extracts using VPAC1 receptor antisera. By immunocytochemistry, VPAC1-R immunostaining was detected in the cytosol and plasma membrane but not the nucleus of fixed mammary tumor tissue. Using laser capture microdissected tumor cells and surface enhanced laser desorption/ionization (SELDI) techniques on mammary tumor cells, the proteomic profile was altered in mice treated with VIPhyb. Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer.

KW - Chemoprevention

KW - Mammary carcinogenesis

KW - Proteomics

KW - Transgenic mice

KW - VIP receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=0347360143&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2003.07.043

DO - 10.1016/j.lfs.2003.07.043

M3 - Article

C2 - 14706566

AN - SCOPUS:0347360143

SN - 0024-3205

VL - 74

SP - 1345

EP - 1357

JO - Life Sciences

JF - Life Sciences

IS - 11

ER -

VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice

Abstract

Keywords

Access to Document

Fingerprint

Cite this